24/7 Wall Street
26 Jul 2026, 16:13 UTC · 1h ago
5 Biggest Earnings Reports to Watch This Week
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
26 Jul 2026, 16:13 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Celestica has raised its FY2026 revenue guidance to $19 billion and adjusted EPS to $10.15. — Significant upward revisions from a key AI infrastructure bellwether signal strong demand and likely positive sentiment for the broader sector.
+0.60Recent sharp price declines in AI-linked names Applied Digital (APLD) and Navitas Semiconductor (NVTS) raise concerns that $700 billion in annual hyperscaler capex expectations may have outrun actual results. — Price action in high-beta AI plays suggests a potential peak in expectations or emerging cracks in the capex narrative.
-0.50Baker Hughes reports a $33.10 billion backlog and $1.4 billion in Power Systems orders specifically tied to data center demand. — Provides concrete evidence that AI infrastructure is driving real-world energy capex and industrial orders.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
Corporate profits are currently growing at a 12.8% year-over-year rate and Q1 2026 GDP accelerated to 2.1%. — Strong macro fundamentals provide a supportive backdrop for risk assets and corporate earnings.
+0.30AstraZeneca faces pressure from China's Volume-Based Procurement (VBP) on Farxiga and is awaiting 20+ Phase III readouts this year. — Regulatory and pipeline risks in a major pharma giant create uncertainty for the stock's near-term trajectory.
-0.20Which stocks this story touches
Significant revenue growth, raised FY2026 guidance, and shares up 98% over one year.
Strong record orders, consecutive EPS beats, and a growing pipeline tied to data center demand.
Despite strong operational growth, shares crashed nearly 34% in the past month.
Shares dropped over 43% in the past month and Q1 revenue declined significantly.
Stock is down year-to-date and the company is facing China VBP pressure on Farxiga.
Mentioned positively in the context of a successful analyst call, though not the focus of current news.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
3h ago
